康基醫療(09997.HK)2024年歸母淨利同比增加15.4%至5.8億元
格隆匯3月24日丨康基醫療(09997.HK)公吿,截至2024年12月31日止年度,公司實現收入人民幣10.09億元,相較2023年增長8.9%。集團銷售額增長乃主要由於一次性產品銷售額增加所致。集團於報吿期內的母公司擁有人應占純利由2023年的人民幣5.04億元增加15.4%至2024年的人民幣5.8億元。有關增加乃主要由於為收入及其他收入及收益增加所致。董事會已議決建議派付截至2024年12月31日止年度的2024年末期股息每股股份人民幣24分。
2024年10月,由福建省牽頭的全國性止血組織結紮夾集中帶量採購結果公佈。此次集中帶量採購涵蓋產品種類廣泛,覆蓋地域廣。集團的全系列結紮夾產品,包括高分子結紮夾、鈦夾、可吸收夾、連發結紮夾及連發鈦夾,均成功中標。公司預計此次全國性集中帶量採購將進一步提升公司產品的市場滲透率,推動進口替代進程,使得公司獲得更大的市場份額。福建省已於2025年2月開始執行集中帶量採購,2025年3月底前將有累計超過10個省份開始執行集中帶量採購。其他省份預計將逐步跟進。
於報吿期內,集團於中國新增16項產品註冊(不計及產品註冊續新)。截至2024年12月31日,集團於中國合共有108項產品獲得中國國家藥品監督管理局(NMPA)註冊,包括17項第三類醫療器械、56項第二類醫療器械以及35項第一類醫療器械。於報吿期內,集團亦於中國取得34項新的專利授權,而唯精醫療則獨立取得79項新專利授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.